| P50 | author | Willem van Eden | Q62042571 |
| | Peter Thomas | Q104733731 |
| P2093 | author name string | Matthias Mack | |
| | Ulrich Mrowietz | |
| | Martin Dugas | |
| | Christian A Sander | |
| | Ruurd van der Zee | |
| | Detlef Schlöndorff | |
| | Martin Röcken | |
| | Enno Christophers | |
| | Gerd Plewig | |
| | Kamran Ghoreschi | |
| | Tilo Biedermann | |
| | Reinhard Mailhammer | |
| | Jörg Prinz | |
| | Susanne Breit | |
| P2860 | cites work | Interleukin-10 and the interleukin-10 receptor | Q24290912 |
| | The IL-4 receptor: signaling mechanisms and biologic functions | Q28198739 |
| | Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial | Q28202251 |
| | The interleukin-10 family of cytokines | Q28212212 |
| | Interleukin 20: discovery, receptor identification, and role in epidermal function | Q28593930 |
| | Functional diversity of helper T lymphocytes | Q29619415 |
| | Inflammatory skin diseases, T cells, and immune surveillance | Q33788959 |
| | Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions | Q33902313 |
| | Tolerance and autoimmunity | Q34167913 |
| | Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines | Q34234920 |
| | The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiat | Q34505900 |
| | Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis | Q35787223 |
| | Interleukin (IL) 4 differentially regulates monocyte IL-1 family gene expression and synthesis in vitro and in vivo | Q36361487 |
| | Antigen-specific activation, tolerization, and reactivation of the interleukin 4 pathway in vivo | Q36363260 |
| | Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease | Q36364080 |
| | Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. | Q36368565 |
| | Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells | Q36368842 |
| | Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for cellular human immunodeficiency virus 1 infection | Q39200565 |
| | Lymphocyte responses and cytokines | Q40620203 |
| | Lymphokine production by human T cells in disease states | Q40661109 |
| | IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease | Q41305674 |
| | Differentiation and stability of T helper 1 and 2 cells derived from naive human neonatal CD4+ T cells, analyzed at the single-cell level | Q42114901 |
| | Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. | Q42642368 |
| | Reversal of established delayed type hypersensitivity reactions following therapy with IL-4 or antigen-specific Th2 cells | Q43682661 |
| | Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. | Q52018451 |
| | Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings. | Q52964524 |
| | Safety evaluation of recombinant human interleukin-4. II. Clinical studies. | Q54568796 |
| | Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial | Q57911995 |
| | CCR5 is characteristic of Th1 lymphocytes | Q59092711 |
| | IL-4 Is a Mediator of IL-12p70 Induction by Human Th2 Cells: Reversal of Polarized Th2 Phenotype by Dendritic Cells | Q62589132 |
| | A strict requirement of interleukin-4 for interleukin-4 induction in antigen-stimulated human memory T cells | Q71420944 |
| | Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis | Q71803269 |
| | Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand | Q73035541 |
| | Selection of conserved TCR VDJ rearrangements in chronic psoriatic plaques indicates a common antigen in psoriasis vulgaris | Q73129277 |
| | Triggering of T cell proliferation through CD28 induces GATA-3 and promotes T helper type 2 differentiation in vitro and in vivo | Q73281771 |
| | Regulation of angiogenesis by the C-X-C chemokines interleukin-8 and epithelial neutrophil activating peptide 78 in the rheumatoid joint | Q73521731 |
| | Psoralen bath plus UV-A therapy. Possibilities and limitations | Q74010742 |
| | New treatments for psoriasis | Q74271067 |
| | IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice | Q74619595 |
| | Cyclosporine consensus conference: with emphasis on the treatment of psoriasis | Q77303806 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | interleukins | Q194908 |
| | autoimmune disease | Q8084905 |
| P304 | page(s) | 40-46 | |
| P577 | publication date | 2002-12-02 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease | |
| P478 | volume | 9 | |